Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
Crinetics Pharmaceuticals, Inc. (CRNX)
Last crinetics pharmaceuticals, inc. earnings: 3/9 04:10 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Tuesday, January 13, 2026 at 9:45 a.m. Pacific Time. To access the live audio-only webcast, click here. The archived webcast will also be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at www.crinetics.com/events. If you are interested in arranging a 1×1 meeting with management, please contact your conference representative. ABOUT CRINETICS PHARMACEUTICALS Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core
Show less
Read more
Impact Snapshot
Event Time:
CRNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRNX alerts
High impacting Crinetics Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRNX
News
- Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026GlobeNewswire
- Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH) [Yahoo! Finance]Yahoo! Finance
- Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)GlobeNewswire
- Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral [Yahoo! Finance]Yahoo! Finance
- Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
CRNX
Earnings
- 11/6/25 - Miss
CRNX
Sec Filings
- 2/2/26 - Form 144
- 1/26/26 - Form 8-K
- 1/13/26 - Form 8-K
- CRNX's page on the SEC website